Behavior of delay times in thrombolytic treatment of patients with acute myocardial infarction
Abstract
Introduction: Occlusion of a coronary artery leads to cell death in a period of time ranging from 4-12 hours, this is a dynamic process that can be modified with the restoration of blood flow in the infarct-related vessel; hence the importance of the ‘time’ factor.
Objective: To determine the delay times in the application of the thrombolytic therapy in patients with acute myocardial infarction.
Method: A prospective longitudinal descriptive study was carried out, including 579 patients diagnosed with ST-segment elevation myocardial infarction who received thrombolytic therapy at the Hospital General Docente Martín Chang Puga in Nuevitas, Camagüey, Cuba; from January 2000 to December 2019. Demographic variables (age and gender) as well as delay times in the application of thrombolysis were assessed.
Results: The predominant age group was 56 to 65 years old (35.2%) as well as males (60.3). Predominant delay times were: patient-time more than two hours, door-to-needle time between 6-12 hours (30.7%), pre-hospital care between 61-180 minutes (56.8%), pain-to-needle time more than 12 hours (34.9%) and overall time to thrombolysis between 6 -12 hours (43.2%).
Conclusions: Delay times in the application of the thrombolytic treatment were, in general, abnormally high. Only in a small percentage of patients it was performed within the first two hours after symptoms onset.
Downloads
References
1. Epidemiology of avoidable delay in the care of patients with acute myocardial infarction in Italy. A GISSI-generated study. GISSI--Avoidable Delay Study Group. Arch Intern Med. 1995;155(14):1481-8.
2. Ministerio de Salud Pública. Anuario Estadístico de Salud 2012. La Habana: Dirección de Registros Médicos y Estadísticas de Salud; 2013.
3. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet. 1986;1(8478):397-402.
4. Scirica BM, Libby P, Morrow DA. Infarto de miocardio con elevación del segment ST: Fisiopatología y evolución clínica. En: Braunwald E, Zipes DP, Libby P, Bonow RO, eds. Tratado de cardiología. Texto de Medicina Cardiovascular. 11ª Ed. Barcelona: Elsevier; 2019. p.1095-122
5. Allen DR, Del Río G, Nariño G, Borrero AI, Reyes MC. Factores asociados a mortalidad y estadía hospitalaria en personas ancianas trombolizadas por infarto miocárdico agudo. MEDISAN [Internet]. 2010 [citado 10 Jun 2021];14(1). Disponible en: http://scielo.sld.cu/pdf/san/v14n1/san10110.pdf
6. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165. DOI: https://doi.org/10.1093/eurheartj/ehy394
7. Olivera Escalona AL. Reperfusión coronaria en el infarto agudo de miocardio con elevación del segmento ST: importancia del contexto y tiempo de aplicación. MEDISAN [Internet]. 2015 [citado 10 Jun 2021];19(10):3056-64. Disponible en: http://medisan.sld.cu/index.php/san/article/view/477/pdf_158
8. Rodríguez Díaz JA, Tamarit Castillo O, Mariol Portuondo R. Comportamiento del tiempo puerta-aguja en el tratamiento trombolítico de pacientes con infarto agudo de miocardio. CorSalud [Internet]. 2021[citado 14 Jun 2021];13(4):421-8. Disponible en: http://www.revcorsalud.sld.cu/index.php/cors/article/view/757/1446
9. Toruncha A, Sánchez C, López Saura P, Pascual MA, Llerena L, Yunes P, et al. Programa nacional de aplicación de la estreptoquinasa recombinante en el infarto del miocardio agudo. Informe preliminar. Biotecnol Apl [Internet]. 1995 [citado 14 Jun 2021];12(3):194-5. Disponible en: https://bit.ly/34fjpIw
10. Martínez Espinosa C. Infarto agudo del miocárdico no complicado. En: Caballero López A. Terapia Intensiva. 2ª Ed. La Habana: ECIMED; 2006. p. 795-808.
11. Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, et al. Standardized end point definitions for coronary intervention trials: The Academic Research Consortium-2 Consensus Document. Circulation. 2018;137(24):2635-50. DOI: https://doi.org/10.1161/circulationaha.117.029289
12. Leyva de la Torre C, Rego Hernández JJ. Causas de la no-trombólisis en el infarto agudo del miocardio y beneficios de su uso. Rev Cuba Farm [Internet]. 2005 [citado 19 Jun 2021];39(2). Disponible en: http://scielo.sld.cu/pdf/far/v39n2/far07205.pdf
13. Hernández L, Valladares F, Coll Y. Terapia trombolítica en pacientes con infarto agudo de miocardio en Cienfuegos. Rev Finlay [Internet]. 2014 [citado 22 Jun 2021];4(1):29-39. Disponible en: http://www.revfinlay.sld.cu/index.php/finlay/article/view/265
14. Abu-Assi E, López A, González V, Redondo A, Peña C, Bouzas N, et al. El riesgo de eventos cardiovasculares tras un evento coronario agudo persiste elevado a pesar de la revascularización, especialmente durante el primer año. Rev Esp Cardiol. 2016;69(1):11-8. DOI: https://doi.org/10.1016/j.recesp.2015.06.016
15. Martínez Benítez P, Valdés Martín A, Chipi Rodríguez Y, Reyes Navia GC, Rodríguez Nande L, Antuña Aguilar T. Características clínicas y estrategias terapéuticas en adultos jóvenes con síndrome coronario agudo, estudio de 8 años. Rev Cuban Cardiol [Internet] 2015 [citado 19 Jun 2021];21(3). Disponible en: http://www.revcardiologia.sld.cu/index.php/revcardiologia/article/view/598/pdf_35
16. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 1997;337(16):1118-23. DOI: https://doi.org/10.1056/nejm199710163371603
17. Greig D, Corbalán R, Castro P, Campos P, Lamich R, Yovaniniz P. Impacto de la trombolisis y de la angioplastia primaria en pacientes con infarto agudo del miocardio tratados en centros hospitalarios terciarios. Rev Méd Chile. 2008;136(9):1098-106. DOI: http://dx.doi.org/10.4067/S0034-98872008000900002
18. Payne JE, Ghadban R, Loethen T, Boyle K, Alpert MA, Madsen R, et al. Impact of left ventricular hypertrophy on peak serum troponin T levels in patients with acute myocardial infarction. Am J Cardiol. 2019;123(11):1745-50. DOI: https://doi.org/10.1016/j.amjcard.2019.02.044
19. Chapman AR, Shah ASV, Lee KK, Anand A, Francis O, Adamson P, et al. Long-term outcomes in patients with type 2 myocardial infarction and myocardial injury. Circulation. 2018;137(12):1236-45. DOI: https://doi.org/10.1161/circulationaha.117.031806
20. Grupo de trabajo de la SEC para el consenso ESC 2018 sobre la cuarta definición universal del infarto de miocardio, Revisores expertos para el consenso ESC 2018 sobra la cuarta definición universal del infarto de miocardio, Comité de Guías de la SEC. Comentarios al consenso ESC 2018 sobre la cuarta definición universal del infarto de miocardio. Rev Esp Cardiol. 2019;72(1):10-5. DOI: https://doi.org/10.1016/j.recesp.2018.11.009
21. Mariani J, De Abreu M, Tajer CD, en representación de los investigadores de la Red para la Atención de Síndromes Coronarios Agudos. Tiempos y utilización de terapia de reperfusión en un sistema de atención en red. Rev Argent Cardiol. 2013;81(3):233-9.
22. Armas NB, Ortega YY, de la Noval R, Suárez R, Llerena L, Dueñas AF. Letalidad por infarto agudo de miocardio en Cuba, 1999- 2008. Rev Cuban Cardiol [Internet]. 2011 [citado 22 Jun 2021];17(1):4-10. Disponible en: http://www.revcardiologia.sld.cu/index.php/revcardiologia/article/view/13
23. Flachskampf FA, Biering-Sørensen T, Solomon SD, Duvernoy O, Bjerner T, Smiseth OA. Cardiac imaging to evaluate left ventricular diastolic function. JACC Cardiovasc Imaging. 2015;8(9):1071-93. DOI: https://doi.org/10.1016/j.jcmg.2015.07.004
24. Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction. Lancet. 2017;389(10065):197-210. DOI: https://doi.org/10.1016/s0140-6736(16)30677-8
25. Popovic B, Agrinier N, Bouchahda N, Pinelli S, Maigrat CH, Metzdorf PA, et al. Coronary embolism among ST-segment-elevation myocardial infarction patients: Mechanisms and management. Circ Cardiovasc Interv [Internet]. 2018 [citado 23 Jun 2021];11(1): e005587. Disponible en: https://doi.org/10.1161/circinterventions.117.005587
26. Nazir S, Elgin E, Loynd R, Zaman M, Donato A. ST-elevation myocardial infarction associated with infective endocarditis. Am J Cardiol. 2019;123(8):1239-43. DOI: https://doi.org/10.1016/j.amjcard.2019.01.033
27. Rozenbaum Z, Elis A, Shuvy M, Vorobeichik D, Shlomo N, Shlezinger M, et al. CHA2DS2-VASc score and clinical outcomes of patients with acute coronary syndrome. Eur J Intern Med. 2016;36:57-61. DOI: https://doi.org/10.1016/j.ejim.2016.09.010
28. Wu E, Lee DC. Evaluación del riesgo tras infarto de miocardio con elevación del segmento ST. Rev Esp Cardiol. 2013;66(8):603-5. DOI: https://doi.org/10.1016/j.recesp.2013.04.007
29. Estess JM, Topol EJ. Fibrinolytic treatment for elderly patients with acute myocardial infarction. Heart. 2002;87(4):308-11. DOI: https://doi.org/10.1136/heart.87.4.308
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.